Hepatitis C New Drugs Review
25.3K views | +7 today
Follow
 
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
Scooped by Krishan Maggon
Scoop.it!

Clinical and Translational Gastroenterology - Hepatitis C Treatment and Barriers to Eradication

Clinical and Translational Gastroenterology - Hepatitis C Treatment and Barriers to Eradication | Hepatitis C New Drugs Review | Scoop.it

Brought to you by the American College of Gastroenterology


Abstract Current treatment for chronic hepatitis C (CHC) is highly efficacious, well-tolerated, and of short duration for the majority of patients. Despite the dramatic advances in therapy, there remain several barriers to disease eradication. These include deficiencies in screening, diagnosis, and access to care, and high cost of the direct-acting antiviral medications. In addition, incident cases and reinfection associated with injection drug use contribute to the persistent worldwide disease burden. This article will review the current CHC treatments, and outline the remaining gaps in therapy and barriers to disease eradication..

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The impact of hepatitis C virus infection on 90-day outcomes following major orthopaedic surgery: a propensity-matched analysis

The impact of hepatitis C virus infection on 90-day outcomes following major orthopaedic surgery: a propensity-matched analysis | Hepatitis C New Drugs Review | Scoop.it
The impact of hepatitis C virus (HCV) infection on outcomes following major orthopaedic interventions, such as joint arthroplasty or spine surgery, has not been effectively studied in the past. Most p
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models

Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models | Hepatitis C New Drugs Review | Scoop.it
Dendritic cell (DC)-derived exosomes (DEXs) form a new class of vaccines for cancer immunotherapy. However, their potency in hepatocellular carcinoma (HCC) remains unknown. Here, we investigated exosomes from HCC antigen-expressing DCs in three different HCC mouse models and proved their feasibility and capability of treating HCC, and thus provide a cell-free vaccine for HCC immunotherapy.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism | Hepatitis C New Drugs Review | Scoop.it
This website links to patient friendly commentary making it easier ​to navigate key HCV data.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection

Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection | Hepatitis C New Drugs Review | Scoop.it
CTAC is Canada’s non-governmental organization led by and for people living with HIV and HIV/HCV co-infection, focusing on access to treatment. Since 1996, we have been working to secure and ensure equitable, affordable and timely access to treatment, care and support for people in Canada living with HIV and HIV/HCV co-infection. We work with community, public, private and not-for-profit leaders to inform research and public policy, and promote public awareness and discussion.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Home - STRIVING TOWARDS THE ELIMINATION OF HCV INFECTION - EASL Monothematic Conference

Home - STRIVING TOWARDS THE ELIMINATION OF HCV INFECTION - EASL Monothematic Conference | Hepatitis C New Drugs Review | Scoop.it
Topics to be covered Epidemiology Strategies for improved HCV testing and diagnosis Management of acute and chronic HCV infection HCV treatment and treatment failures The means to reach the WHO targets for HCV elimination The challenge of post-SVR management Key dates 06 Nov 2017 Abstract...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review | Hepatitis C New Drugs Review | Scoop.it
The burden of hepatitis C virus (HCV) infection is escalating among people who inject
drugs (PWID), yet testing and treatment remains suboptimal. The aim of this systematic
review was to evaluate the effectiveness of interventions to enhance HCV testing,
linkage to care, and treatment uptake among PWID.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Virus-Induced Autophagy and Host Innate Immune Response

Hepatitis C Virus-Induced Autophagy and Host Innate Immune Response | Hepatitis C New Drugs Review | Scoop.it
Autophagy is a catabolic process that is important for maintaining cellular homeostasis. This pathway in hepatocytes is stimulated and controlled by the hepatitis C virus (HCV)—upon infection—to promote its own replication. HCV induces autophagy indirectly and directly through different mechanisms and temporally controls the autophagic flux. This enables the virus to maximize its replication and attenuate the innate immune responses that it activates. In this review, we discuss the relationship between HCV and autophagy, and the crosstalk between HCV-induced autophagy and host innate immune responses.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Drug interactions in HIV-infected patients treated for hepatitis C

Drug interactions in HIV-infected patients treated for hepatitis C | Hepatitis C New Drugs Review | Scoop.it
(2017). Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opinion on Drug Metabolism & Toxicology: Vol. 13, No. 8, pp. 807-816. doi: 10.1080/17425255.2017.1351942
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States | Hepatitis C New Drugs Review | Scoop.it
(2017). Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. Journal of Medical Economics. Ahead of Print. doi: 10.1080/13696998.2017.1360313
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

PCPs Can Effectively Manage HCV Treatment with DAAs

PCPs Can Effectively Manage HCV Treatment with DAAs | Hepatitis C New Drugs Review | Scoop.it
In a 600-patient study, PCPs and NPs were shown to be just as effective as specialists in HCV treatment with direct-acting antivirals.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Shortening the duration of therapy for chronic hepatitis C infection

Shortening the duration of therapy for chronic hepatitis C infection | Hepatitis C New Drugs Review | Scoop.it
Combination direct-acting antiviral therapy of 8–24 weeks is highly effective for
the treatment of chronic hepatitis C infection. However, shortening the treatment
duration to less than 8 weeks could potentially reduce overall treatment costs and
improve adherence. Here we explore the arguments for and against the development of
short-duration regimens and existing data on treatment for 6 weeks or less among patients
with chronic hepatitis C virus genotype 1 infection. Additionally, we identify potential
predictors of response to short-course combination therapies with direct-acting antiviral
drugs that might be explored in future clinical trials.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture

Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture | Hepatitis C New Drugs Review | Scoop.it
Article
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis

Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis | Hepatitis C New Drugs Review | Scoop.it
Patients with hepatitis C virus (HCV)-associated cirrhosis and clinical significant
portal hypertension (CSPH, hepatic venous pressure gradient [HVPG] 10 mmHg or greater),
despite achieving sustained virological response (SVR) to therapy, remain at risk
of liver decompensation. We investigated hemodynamic changes following SVR in patients
with CSPH and whether liver stiffness measurements (LSMs) can rule out the presence
of CSPH.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The Impact of the Hepatitis B Core Antibody Status on Recurrence in Patients with Non-B Non-C Hepatocellular Carcinoma after Curative Surgery

The Impact of the Hepatitis B Core Antibody Status on Recurrence in Patients with Non-B Non-C Hepatocellular Carcinoma after Curative Surgery | Hepatitis C New Drugs Review | Scoop.it
Abstract Background: The serum antibody to hepatitis B core antigen (HBcAb) is considered a risk factor of liver carcinogenesis. This study aimed to reveal whether HBcAb status is a prognostic factor after hepatectomy is performed for treating hepatocellular carcinoma (HCC). Methods: This retrospective study enrolled 272 patients who underwent hepatectomy as the initial treatment for HCC and who were followed up over 5 years after surgery. The types of HCC were classified into the following 3 types according to the hepatitis virus infection status and the patients without hepatitis virus infection non-B non-C HCC (NBNC-HCC) were further classified into 2 groups. Results: There is no novel finding as a result of the comparison made among hepatitis virus status. Of 90 patients (33.1%) with NBNC-HCC, 10 patients were excluded because the preoperative HBcAb status was not measured. There were 51 patients (63.8%) who were HBcAb-positive and 29 patients (36.2%) who were HBcAb-negative. In multivariate analysis, the presence of HBcAb-negative (hazard ratio 2.10, 95% CI 1.09-4.03, p = 0.026) remained as significant independent risk factors for recurrence in NBNC-HCC. Conclusions: This study shows that the HBcAb-positive is rather a favorable predictor for recurrence after curative resection in NBNC-HCC.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

How far industry is from assembling a functional cure in HBV

How far industry is from assembling a functional cure in HBV | Hepatitis C New Drugs Review | Scoop.it
Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the virus that persist on standard of care.Data on combinations that add a single MOA to standard of care will begin to read out over the next 18 months. More complex combinations, including cocktails combining novel mechanisms, are a few years away.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes

AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes | Hepatitis C New Drugs Review | Scoop.it
MONTREAL, Aug. 17, 2017- AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead has directly cured 1.5 million HCV patients – just another 70 million to go, says Michael Mertens

Gilead has directly cured 1.5 million HCV patients – just another 70 million to go, says Michael Mertens | Hepatitis C New Drugs Review | Scoop.it
With the approval of Vosevi (sofosbuvir/velpatasvir/voxilaprevir) in the USA and Europe last month, US biotech giant Gilead Sciences has now brought to market f
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial | Hepatitis C New Drugs Review | Scoop.it
Our results show that 99% of patients treated with once-daily glecaprevir plus pibrentasvir
achieved a sustained virological response at 12 weeks. Furthermore, this drug regimen
had a favourable safety profile in previously treated or untreated patients with chronic
HCV genotype 1, 2, 4, 5, or 6 infection and compensated cirrhosis. These findings
could help simplify treatment algorithms and reduce treatment burden.
Krishan Maggon 's insight:
Lancet Published: 14 August 2017 
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial 

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments

Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments | Hepatitis C New Drugs Review | Scoop.it
In 2015, the Coalition to Eradicate Viral Hepatitis in Asia Pacific gathered leading
hepatitis experts from Bangladesh, India, Indonesia, Malaysia, Pakistan, the Philippines,
and Thailand to discuss common challenges to the burden posed by hepatitis B virus
(HBV) and hepatitis C virus (HCV), to learn from each other's experience, and identify
sustainable approaches. In this report, we summarise these discussions. Countries
differ in their policy responses to HBV and HCV; however, substantial systemic, cultural,
and financial barriers to achievement of elimination of these infections persist in
all countries.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cocrystal Pharma Hepatitis C picomolar inhibitor of NS5A

Cocrystal Pharma Hepatitis C picomolar inhibitor of NS5A | Hepatitis C New Drugs Review | Scoop.it
Developing a series of compounds that are potent non-nucleoside and nucleoside inhibitors of hepatitis C NS5B RNA dependent RNA polymerase, a replication enzyme that is essential to viral replication and is highly conserved between all hepatitis C genotypes. Therefore, inhibitors of this enzyme are likely to have multi- or pan-genotypic activity.

We are also developing compounds that inhibit hepatitis C NS5A and NS5B, two enzymes that are essential for viral replication. Cocrystal Pharma has identified a picomolar inhibitor of NS5A, another essential viral replication protein. Inhibitors of NS5A, in combination with nucleosides, have demonstrated excellent efficacy in treatment for hepatitis C in comparison with standard care. 

 Our compounds that target NS5B hepatitis C polymerase, NS5A and will be developed as a combination treatment. Such a combination treatment might have higher antiviral activity or a higher barrier to viral resistance than either treatment alone.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic

High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic | Hepatitis C New Drugs Review | Scoop.it
Though direct acting antivirals (DAAs) promise high cure rates, many providers and
payers remain concerned about successful treatment for people who use drugs (PWUD),
even among those engaged in opioid agonist treatment (OAT). The efficacy of DAAs among
PWUD in real-world settings is unclear.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Combating hepatitis B and C to reach elimination by 2030

Combating hepatitis B and C to reach elimination by 2030 | Hepatitis C New Drugs Review | Scoop.it
Advocacy brief on viral hepatitis: Combating hepatitis to reach elimination by 2030
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

London's calling: Let's eliminate Hepatitis C from group up

London's calling: Let's eliminate Hepatitis C from group up | Hepatitis C New Drugs Review | Scoop.it
MEDIA ROOM > LONDON'S CALLING: LET'S ELIMINATE HEPATITIS C FROM GROUP UP LONDON'S CALLING: LET'S ELIMINATE HEPATITIS C FROM GROUP UP Blenheim is a leading charity working across London to reduce the harm caused by drug and alcohol use to individuals and communities (blenheimcdp.org.uk).
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Treatment with PTEN-Long protein inhibits hepatitis C virus replication - ScienceDirect

Treatment with PTEN-Long protein inhibits hepatitis C virus replication - ScienceDirect | Hepatitis C New Drugs Review | Scoop.it
Publication date: November 2017
Source:Virology, Volume 511
Author(s): Qi Wu, Zhubing Li, Qiang Liu
Hepatitis C virus (HCV) infection is a confirmed risk factor for hepatocellular carcinoma (HCC). Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) possesses tumor suppression function that is frequently defective in HCC tumors. PTEN-Long, a translation isoform of PTEN, functions in a cell non-autonomous manner. In this study, we demonstrated that intracellular overexpression of PTEN-Long inhibits HCV replication. More importantly, we showed that treatment with extracellular PTEN-Long protein inhibits HCV replication in a dose-dependent manner. Furthermore, we showed that PTEN-Long interacts with HCV core protein and this interaction is required for HCV replication inhibition by PTEN-Long. In summary, we demonstrated, for the first time, that PTEN-Long protein, an isoform of the canonical PTEN and in the form of extracellular protein treatment, inhibits HCV replication. Our study offers an opportunity for developing additional anti-HCV agents.
Krishan Maggon 's insight:
Treatment with PTEN-Long protein inhibits hepatitis C virus replication . 

Virology Volume 511, November 2017, Pages 1-8
more...
No comment yet.